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In addition, studies have been performed that investigated correlations between TEG/ROTEM parameters and the occurrence of bleeding in these patients. [7] [8] [9] For example, in a small number of patients with cirrhosis who presented with acute variceal bleeding, specific parameters of TEG (R-time, K-time, and α-Angle) indicated more hypocoagulable features in those who experienced early rebleeding. In contrast, none of the standard laboratory tests of hemostasis (international normalized ratio (INR), activated partial thromboplastin time (aPTT), or platelet count) differed between those who rebled and those who did not. In the present study, we measured the baseline hemostatic phenotype by TEG in a large group of patients with cirrhosis. The aim was to better define the hemostatic status of patients with cirrhosis across a variety of etiologies and severity of disease. In addition, we investigated possible correlations between TEG, bleeding and thrombosis, but also with disease outcome, since it has been proposed that intrahepatic thrombosis contributes to a progressive disease course in patients with cirrhosis.
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| PATIENTS & METHODS
Two hundred seventy consecutive outpatients with cirrhosis were prospectively studied at the Virginia Commonwealth University (VCU) 
| Definition of complications and final outcomes of cirrhosis
Patients were seen every 6 months (for Child's class A patients) or at least every 3 months (for Child's class B/C patients) as a matter of routine by one investigator (RTS). Electronic medical records were reviewed on each visit, and patients were specifically asked whether they had any "bleeding or clotting" complications during the interim. Medical records from outside institutions and physicians were requested in the event of a positive response from a patient when the complication occurred at a hospital other than VCU Medical Center.
Bleeding complications specifically included spontaneous (nonprocedure-related) gastrointestinal bleeding from any source, the need for blood transfusion with evidence of blood loss, or other significant blood loss. Epistaxis was not included in the assessment of bleeding complication unless it required intervention. Thrombotic complications specifically included spontaneous (non-procedure-related) deep venous thrombosis of the arms legs and/or pulmonary embolism or new occlusive portal venous thrombosis on ultrasound during 6-month surveillance exams for hepatocellular carcinoma. Final outcomes of cirrhosis included transplant-free survival, orthotopic liver transplantation (OLT), or death.
| Thromboelastography
Thromboelastography was performed on a single instrument (Thrombelastograph Haemostasis Analyzer 5000; Haemonetics Corp.,
Haemoscope Division, Niles, IL, USA). Briefly, 5 mL of 3.2% citrated whole blood was subjected to TEG within 2 hour of blood draw.
Clotting was initiated at 37°C by the addition of 40 μL of kaolin to . Kinetic changes in clot formation and clot dissolution were measured for 30 minute after reaching maximal clot firmness. Five parameters were recorded (see Figure 1 and Table 1 ).
An abnormal TEG parameter was defined as an R-or K-time above the upper limit of normal, or an α-Angle or MA below the lower limit of normal for our laboratory, which are similar to other series. (11) 57 (11) 59 (7) 58 (12) 55 (14) 57 (13) 57 ( (4) 13 (5) 12 (4) 13 (6) 14 (5) 13 (5) 13 (5) Laboratory blood tests Hemoglobin, g/dL 11.8 (2.3)
| Statistical analysis
12.2 (2) 12 (2) 12.7 (1.9)
(7)
Platelet count, ×10 (15) 137 (3) 138 (1) 137 (1) 138 (4) 137 (4) 137 ( encephalopathy, 3% thrombosis, and 11% suffered from bleeding complications. At the end of the study, 71% of the patients had been hospitalized, 19% underwent liver transplantation, and 46% died.
The mean time from performing TEG to bleeding was 347 days and 72 days to thrombosis. It was 328 days to liver transplantation and 484 days to death. Patients in the cholestatic patient group were up to 10 time less likely to develop encephalopathy (3%), but 2-3 times more likely to undergo liver transplantation (44%) compared to patients suffering from other etiologies of cirrhosis, whilst the distribution among classes of disease severity between the groups was similar (ie, Child-Pugh and MELD).
| Normal R-times in cirrhosis regardless of the etiology
In Figure 2A , it is shown that the R-time, indicating the latency of clot formation, was generally within normal range when patients were combined, with a median (range) of 4.3 minute (1-9.7) (normal range Figure 3A ).
| Normal-to-increased K-times in cirrhosis regardless of etiology, with lowest values in cholestatic cirrhosis
In Figure 2B , it is shown that the K-time, the time to initial fibrin for- 
| Normal-to-decreased α-Angles in cirrhosis regardless of etiology, with highest values in cholestatic cirrhosis
In Figure 2C , it is shown that the α-Angle, indicating the speed of clot 
| Normal-to-decreased MA in non-cholestatic cirrhosis, but normal-to-increased values in cholestatic cirrhosis
In Figure 2D , it is shown that the MA, indicating maximal clot strength, was decreased in 45% of patients combined, normal in 52%, and el- 
| Normal Ly-30 in cirrhosis regardless of the etiology
In Figure 2E , it is shown that the Ly Table 3 . Platelet count, fibrinogen levels, as well as INR also associated with disease severity as shown in Figure 3F -H.
| K-time, α-
| TEG parameters at admission do not predict thrombosis, bleeding events, and transplantation or death in patients with cirrhosis
As shown in Figure 4 , TEG parameters at baseline did not significantly differ between patients who experienced thrombosis or bleeding events during follow-up or between patients that underwent transplantation or died compared to those who survived during followup. Nevertheless, the limited number of patients that experienced a thrombotic event during follow-up had a lower median R-and K-time and higher median MA and α-Angle at baseline compared to the median of those who did not suffer from thrombosis. Also, no associations with outcome were found when groups with different etiologies were investigated separately or when patients with Child-Pugh B and C cirrhosis were combined into a single group (ie, with advanced disease at baseline) (data not shown).
| DISCUSSION
The above study of kaolin-initiated TEG shows a generally preserved function of the hemostatic system in cirrhosis. This is in line with earlier studies using TEG in patients with cirrhosis. 5, 13 Nevertheless, this is the largest study of TEG in cirrhosis so far, which allowed comparison between groups with different etiologies of underlying liver disease, but with similar baseline characteristics.
In addition, data on outcome were gathered prospectively over an average period of almost 3 years to investigate the predictive potential of the test for bleeding, thrombosis, and liver transplantation and/or death.
We found that regardless of etiology, the majority of patients with cirrhosis had TEG parameters within normal reference range, whereas a significant proportion also had parameters outside the normal range.
Hypocoagulable features reflected by increased K-time and decreased
α-Angle and MA were found in 16-45% of patients. The latter was not reflective of the cohort as a whole. Indeed, compared to the other etiologies, TEG values in patients with cholestatic liver disease were significantly different. This group demonstrated hypercoagulable tendencies, notably increased MA values above the normal upper limit, probably because of higher fibrinogen concentrations and platelet count compared to the other etiologies in combination with platelet hyperreactivity, which is in accordance with previous studies. 6, 14 Ultimately, however, clot dissolution 30 minute after MA was well within normal limits in all groups. In addition, despite some patients having abnormal TEG measurements on admission, this had no implication for their clinical outcome: TEG parameters between patients that did or did not experience bleeding, thrombosis, death and/or liver transplantation were similar, indicating that the test has no value in predicting these events.
We and others have systematically shown that primary and secondary hemostasis are preserved in cirrhosis, with distinct hypercoagulable features, and the present study adds up to the concept of a rebalanced hemostatic system in cirrhosis. We have first demonstrated that elevated levels of the platelet adhesive protein von Willebrand factor (over)compensate for abnormalities in platelet number and function.
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Others have subsequently shown that the thrombin generating capacity in blood samples taken for patients with cirrhosis was preserved 3 (even increased in advanced cirrhosis [16] [17] [18] ), as a consequence of a simultaneous decrease in pro-and anticoagulant factors. More importantly, these laboratory studies have contributed to a major shift in the understanding of the clinical consequences of cirrhosis-associated coagulopathy.
Expert opinion now suggests that bleeding in many (surgical) cases are/ were more likely due to hemodynamic changes in patients with cirrhosis than to an underlying hemostatic disorder. 2 It is now also acknowledged that patients with cirrhosis are not "auto-anticoagulated"; they are not protected from thrombotic events even when PT/INR and aPTT are prolonged, or when platelet counts are low. 19 In fact, it is increasingly recognized that thrombosis can be a major complicating factor in cirrhosis 20 and may even contribute to disease progression.
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While the results of this study confirm relatively preserved hemostasis in patients with cirrhosis of diverse etiologies, it raises some concerns on how to interpret abnormal TEG results in stable patients with cirrhosis. Notably, the lack of correlation with clinical outcome needs further appreciation, because ultimately this questions the utility of TEG in patient management beyond routine diagnostic tests of hemostasis and the operation theater. So far, there is only evidence that TEG might be useful in detecting an invasive procedure-related bleeding or thrombotic risk in cirrhotic patients 8, 9, 22, 23 , as well as early rebleeding following sclerotherapy. 7 A recent randomized study looking at patients with cirrhosis undergoing invasive procedures, compared standard hemostasis screening tests (platelet count and PT) with TEG. It showed that the latter was more useful in deciding whether allogenic blood product transfusion was necessary. 24 One of the reasons why TEG has not proven useful in stable patients with cirrhosis is that it is still not sophisticated enough detect the full range of potential changes in the hemostatic system. This logically hampers accurate (long-term) prediction of thrombosis or bleeding, although the lack of association between low K-time/α-Angle/MA and bleeding reported here can easily be explained by the current notion that bleeding in cirrhosis is usually secondary to hemodynamic changes (ie, variceal bleeding due to increased pressure in the splanchnic venous system). Kaolin-modified TEG is inherently limited by its initiation of the intrinsic clotting cascade which does not reflect physiological (tissue-factor driven [TF]) clotting dynamics. However, even in TF-triggered TEG, the absence of thrombomodulin prohibits protein C activation during clot formation, and therefore TEG does not fully reflect the balance between pro-and anticoagulant drivers. Also, while TEG can be useful in recognizing a hyperfibrinolysis-related bleeding risk, it is not designed to detect a potential thrombotic risk driven by hypofibrinolysis. We have recently shown that clots from patients with cirrhosis are less permeable compared to healthy individuals despite impaired clot formation, and hence these are relatively resistant to lysis. 25 The proposed underlying mechanism is that a reduced potential of fibrinolytic proteins to permeate through the clot increases the risk of thrombus development. Failure to detect thrombogenic clot phenotypes in cirrhosis may also partly explain why the TEG has not proven useful in predicting outcome in this study.
A simpler explanation as to why we did not find a correlation between TEG and clinical outcome is that the incidence of thrombosis was either too low to detect one or that the time period between TEG measurements and measures of outcome was too long. In the present study, thrombosis incidence was 3%, and interestingly, there were no cases of thrombosis in cholestatic disease group, which clearly stood apart by demonstrated hypercoagulable features of TEG. Moreover, there were only two cases of thrombosis in the HCC group, while it is well known that malignancies are associated with an increased risk of thrombotic events. The low incidence of thrombotic events in our study was not necessarily lower than previous studies of venous thrombosis in cirrhosis (incidence of 0.5-6.5%) 16, [26] [27] [28] , but nevertheless highlights that it will be extremely difficult to predict thrombotic events in the general cirrhotic population. Also, because the clinical phenotype of patients may be altered radically during disease progression, there will be variations in thrombotic or bleeding risk over time, which makes it difficult to identify the ideal time point for TEG measurement in the individual patient. Preferably, future prospective studies would incorporate serial TEG measurements to identify the time window wherein the test has predictive potential. In addition, to validate the test as a predictor of thrombosis and/or disease progression, a critical first move forward will be to identify target groups that have high risk for thrombotic events in the short-term. One approach would be to adopt the PADUA prediction score that identifies admitted patients at high-risk for VTE 29 and to compare it with TEG in a randomized study of VTE risk detection in hospitalized patients with cirrhosis. Prospectively, TEG could even guide thromboprophylaxis by measuring individual and potentially supra-/sub-clinical response to therapy.
In conclusion, a single kaolin-activated TEG measurement does not predict future bleeding or thrombosis in stable patients with cir- 
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